# An Expanded Access Program to Provide Sugemalimab for the Treatment of Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (R/R ENKTL)

> **NCT05131438** · — · NO_LONGER_AVAILABLE · sponsor: **EQRx International, Inc.**

## Conditions studied

- Extranodal NK/T-cell Lymphoma

## Interventions

- **DRUG:** sugemalimab

## Key facts

- **NCT ID:** NCT05131438
- **Lead sponsor:** EQRx International, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2023-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05131438

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05131438, "An Expanded Access Program to Provide Sugemalimab for the Treatment of Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (R/R ENKTL)". Retrieved via AI Analytics 2026-09-08 from https://api.ai-analytics.org/clinical/NCT05131438. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*